공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 자가면역 질환 및 염증성 질환 면역조절제 시장(2016-2020년)

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2016년 11월 상품 코드 387468
페이지 정보 영문 98 Pages
가격
US $ 2,500 ₩ 2,804,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,365,000 PDF (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,486,000 PDF (Enterprise license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,730,000 PDF (Global license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 자가면역 질환 및 염증성 질환 면역조절제 시장(2016-2020년) Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020
발행일 : 2016년 11월 페이지 정보 : 영문 98 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 자가면역 질환 및 염증성 질환 면역조절제 시장은 2016-2020년간 7.01%의 연평균 성장률(CAGR)로 확대될 전망입니다. 면역조절제는 면역계를 조절하는 약제로서 많은 약제가 출시되어 있는데, 류마티스 관절염, 궤양성 대장염, 크론병 등 일부 질환을 완치시키는 약제가 없기 때문에 현재 더 큰 미충족 요구가 존재합니다.

세계의 자가면역 질환 및 염증성 질환 면역조절제(Immunomodulator) 시장에 대해 조사했으며, 2020년까지 성장 전망, 벤더 동향, 지역별 동향, 시장의 주요 벤더 프로파일 등을 정리하여 전해드립니다.

제1장 주요 요약

제2장 본 보고서의 범위

제3장 시장 조사 방법

제4장 서론

제5장 자가면역 질환과 염증성 질환

  • 류마티스 관절염
  • 염증성 장질환(IBD)
  • 주요 면역조절제

제6장 파이프라인 포트폴리오

제7장 시장 현황

  • 시장 개요
  • 시장 규모와 예측
  • Five Forces 분석

제8장 질환별 시장 세분화

  • 류마티스 관절염
  • 염증성 장질환(IBD)

제9장 분자 종류별 시장 세분화

  • 생물학적 면역조절제
  • 소분자 면역조절제

제10장 지역별 세분화

  • 지역별 시장
  • 아메리카
  • 유럽, 중동 및 아프리카
  • 아시아태평양 지역

제11장 시장 동향

  • TNF 알파 저해제 및 B세포 저해제 보급
  • 혁신적 기술을 이용한 신규 치료제 개발
  • 개량된 진단 툴이 치료를 요구하는 인구 증가 촉진

제12장 성장 촉진요인의 영향

제13장 시장이 해결해야 할 과제

  • 개발중인 약제 중단이 매출을 큰 폭으로 감소시켜
  • 대체 치료법의 인기 상승이 시장 성장 저해
  • 약제의 부작용

제14장 성장 촉진요인과 과제의 영향

제15장 시장 동향

제16장 벤더 환경

  • 경쟁 시나리오
  • 기타 주목해야 할 벤더

제17장 주요 벤더 분석

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer

제18장 부록

제19장 Technavio 소개

LSH 16.11.21

About Autoimmune and Inflammatory Immunomodulators

Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Technavio's analysts forecast the global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer

Other Prominent Vendors

  • AstraZeneca
  • Avaxia Biologics
  • Biogen Idec
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Eli Lilly
  • Enlivex Therapeutics
  • Gilead Sciences
  • Immune Pharmaceuticals
  • Merck
  • Mitsubishi Tanabe Pharma
  • Neovacs
  • Prometheus Laboratories
  • Sandoz
  • Sanofi
  • Swedish Orphan Biovitrum
  • Takeda Pharmaceuticals
  • UCB

Market driver

  • Development of novel therapies using innovative technologies.
  • For a full, detailed list, view our report

Market challenge

  • Discontinuation of drugs under development leading to substantial loss in revenue.
  • For a full, detailed list, view our report

Market trend

  • Advent of biosimilars expected to improve the treatment rates.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Autoimmune and inflammatory diseases

  • Rheumatoid arthritis
  • IBD
  • Top immunomodulators for rheumatoid arthritis and IBD

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type of disease

  • Global rheumatoid arthritis immunomodulators market
  • Global IBD immunomodulators market

PART 09: Market segmentation by molecule type

  • Global autoimmune and inflammatory biologic immunomodulators market
  • Global autoimmune and inflammatory small molecule immunomodulators market

PART 10: Geographical segmentation

  • Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
  • Autoimmune and inflammatory immunomodulators market in Americas
  • Autoimmune and inflammatory immunomodulators market in EMEA
  • Autoimmune and inflammatory immunomodulators market in APAC

PART 11: Market drivers

  • Strong adoption of TNF-alpha inhibitors and B-cell inhibitors
  • Development of novel therapies using innovative technologies
  • Improved diagnostic tools increase the treatment-seeking population

PART 12: Impact of drivers

PART 13: Market challenges

  • Discontinuation of drugs under development leading to substantial loss of revenue
  • Growing popularity of alternative treatment procedures hinders the market growth
  • Adverse effects of the drugs

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Emergence of oral agents likely to improve patient outcomes
  • Advent of biosimilars expected to improve the treatment rates
  • Focus on regenerative medicines
  • Strategic alliances and acquisitions

PART 16: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 17: Key vendor analysis

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Different classes of immunosuppressant drugs based on their mechanism of action
  • Exhibit 03: Key buying criteria for global autoimmune and inflammatory immunomodulators market 2015
  • Exhibit 04: Key customer segments of autoimmune and inflammatory immunomodulators market
  • Exhibit 05: Etiology of autoimmune diseases
  • Exhibit 06: Pipeline portfolio: Rheumatoid arthritis immunomodulators
  • Exhibit 07: Pipeline portfolio: Ulcerative colitis immunomodulators
  • Exhibit 08: Pipeline portfolio: Crohn's disease immunomodulators
  • Exhibit 09: Global autoimmune and inflammatory immunomodulators market snapshot: Developed and emerging markets 2015
  • Exhibit 10: Factors influencing global autoimmune and inflammatory immunomodulators market
  • Exhibit 11: Approval and patent expiries of top-selling biologics
  • Exhibit 12: Impact of factors affecting the market 2015 and 2020
  • Exhibit 13: Global autoimmune and inflammatory immunomodulators market 2015-2020 ($ billions)
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Segmentation of global autoimmune and inflammatory immunomodulators by type of disease based on revenue 2015
  • Exhibit 16: Global autoimmune and inflammatory immunomodulators market by disease type 2015-2020
  • Exhibit 17: Global rheumatoid arthritis immunomodulators market 2015-2020 ($ billions)
  • Exhibit 18: Opportunities across rheumatoid arthritis industry
  • Exhibit 19: Global IBD immunomodulators market 2015-2020 ($ billions)
  • Exhibit 20: Global IBD therapeutics market segmentation growth lifecycle analysis
  • Exhibit 21: Global IBD immunomodulators market by disease type 2015-2020
  • Exhibit 22: Global ulcerative colitis immunomodulators market 2015-2020 ($ billions)
  • Exhibit 23: Global Crohn's disease immunomodulators market 2015-2020 ($ billions)
  • Exhibit 24: Comparative graph of global autoimmune and inflammatory immunomodulators market by molecule type ($ billions)
  • Exhibit 25: Global autoimmune and inflammatory biologic immunomodulators market 2015-2020 ($ billions)
  • Exhibit 26: Biologicals approvals by the US FDA
  • Exhibit 27: Global rheumatoid arthritis biologic immunomodulators market 2015-2020 ($ billions)
  • Exhibit 28: Global IBD biologic immunomodulators market 2015-2020 ($ billions)
  • Exhibit 29: Global autoimmune and inflammatory small molecule immunomodulators market 2015-2020 ($ billions)
  • Exhibit 30: Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
  • Exhibit 31: Global autoimmune and inflammatory immunomodulators market segmentation by geography 2015-2020 ($ billions)
  • Exhibit 32: Global share of autoimmune and inflammatory immunomodulators market by geography 2015
  • Exhibit 33: Global autoimmune and inflammatory immunomodulators market segmentation by region: Market growth lifecycle analysis 2015
  • Exhibit 34: Global autoimmune and inflammatory immunomodulators market: Country analysis based on revenue and growth rate
  • Exhibit 35: Opportunity analysis of autoimmune and inflammatory immunomodulators market in Americas
  • Exhibit 36: Autoimmune and inflammatory immunomodulators market in Americas 2015-2020 ($ billions)
  • Exhibit 37: Opportunity analysis of autoimmune and inflammatory immunomodulators market in EMEA
  • Exhibit 38: Autoimmune and inflammatory immunomodulators market in EMEA 2015-2020 ($ billions)
  • Exhibit 39: Opportunity analysis of autoimmune and inflammatory immunomodulators market in APAC
  • Exhibit 40: Autoimmune and inflammatory immunomodulators market in APAC 2015-2020 ($ billions)
  • Exhibit 41: Sales performance of key TNF-alpha inhibitors and B-cell inhibitors ($ billions)
  • Exhibit 42: Key vendors: Developing novel therapies
  • Exhibit 43: Key developments leading to improved diagnostics
  • Exhibit 44: Impact of drivers
  • Exhibit 45: List of few immunomodulators that were discontinued from development or market
  • Exhibit 46: CAM therapies for rheumatoid arthritis
  • Exhibit 47: Usage of CAM therapies in US adults
  • Exhibit 48: List of CAM therapies and items used in Crohn's disease and ulcerative colitis
  • Exhibit 49: List of adverse side effects associated with rheumatoid arthritis
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Key marketed and pipeline oral agents
  • Exhibit 52: List of few biosimilars under development for various indications
  • Exhibit 53: List of few regenerative medicines under development for rheumatoid arthritis and IBD
  • Exhibit 54: Key deals in global immunomodulators market
  • Exhibit 55: Market share of key vendors 2015
  • Exhibit 56: Geographical presence of key vendors
  • Exhibit 57: Competitive scenario of global autoimmune and inflammatory immunomodulators market vendors 2015-2020
  • Exhibit 58: AbbVie: Strength assessment
  • Exhibit 59: AbbVie: Strategy assessment
  • Exhibit 60: AbbVie: Opportunity assessment
  • Exhibit 61: AbbVie: YoY growth and revenue of Humira 2013-2015 ($ billions)
  • Exhibit 62: Johnson & Johnson: Strength assessment
  • Exhibit 63: Johnson & Johnson: Strategy assessment
  • Exhibit 64: Johnson & Johnson: Opportunity assessment
  • Exhibit 65: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
  • Exhibit 66: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
  • Exhibit 67: Amgen: Strength assessment
  • Exhibit 68: Amgen: Strategy assessment
  • Exhibit 69: Amgen: Opportunity assessment
  • Exhibit 70: Amgen: YoY revenue and growth rate of Enbrel (in the US and Canada) 2013-2015 ($ billions)
  • Exhibit 71: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 72: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 73: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan for immunology segment 2013-2015 ($ billions)
  • Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue of Actemra/RoActemra for immunology segment 2013-2015 ($ billions)
  • Exhibit 76: Pfizer: Strength assessment
  • Exhibit 78: Pfizer: Strategy assessment
  • Exhibit 79: Pfizer: Opportunity assessment
  • Exhibit 80: Pfizer: Global autoimmune and inflammatory immunomodulators revenues 2014-2015 ($ billions)
Back to Top
전화 문의
F A Q